Skip to content
Medical Health Aged Care

AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing

AdvanCell 4 mins read
  • Media:
SYDNEY--BUSINESS WIRE--

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing. This milestone funding round was co-led by SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis.Additional support came from existing investor Morningside, alongside new investors Tenmile, Brandon Capital, and others.

Since its founding in June 2019, AdvanCell has grown from a belief in the potential of Targeted Alpha Therapy into a global organisation with 60 passionate team members, a 40,000-square-foot manufacturing facility, world-class pre-clinical infrastructure, a potentially best-in-class drug for prostate cancer that is in trials, and a deep and developing pipeline of assets.

This investment will fuel AdvanCell’s ongoing efforts to expand its manufacturing capacity, accelerate the clinical development of its pipeline of radionuclide therapies, and advance its mission of delivering life-changing treatments to cancer patients worldwide.

AdvanCell is currently enrolling patients for the highest dose cohort of its multi-center TheraPb Ph I/II dose escalation clinical trial of ADVC001 for metastatic prostate cancer, a potentially best-in-class Targeted Alpha Therapy. The trial aims to demonstrate the safety and efficacy of Pb-212-based radionuclide treatment.

As part of the financing, Jamil M. Beg from SV Health Investors, Christopher Gagliardi from Sanofi Ventures, and Bali Muralidhar from Abingworth have joined the AdvanCell Board of Directors. They bring extensive industry expertise to support the company’s growth and join existing directors Bill Ferris AC, Anthony Aiudi, Kevin Cameron, and Andrew Adamovich.

Jamil M. Beg, Partner at SV Health Investors, commented:

“We are delighted to support AdvanCell’s growth and play a role in its remarkable journey through leading this oversubscribed Series C. We have looked long and deep at the field of radionuclide therapies and are confident that AdvanCell stands out with a first-in-class Pb-212-PSMA program and a best-in-class manufacturing platform. The company’s exceptional team, technologies, robust infrastructure, collaborations with some of the world’s largest pharma companies and ability to consistently execute, position it to truly change outcomes for patients. We are excited to help AdvanCell realize its potential in transforming cancer care globally.”

AdvanCell was founded on the belief that Targeted Alpha Therapies could change the course of cancer treatment and that the scalable supply of isotopes would enable the development of multiple practice-changing drugs. Radionuclide therapies for prostate cancer and gastroenteropancreatic neuroendocrine tumours have transformed patient care. Pb-212 Targeted Alpha Therapy has the potential to further advance this progress by leveraging the radiobiological and physical attributes of Pb-212 to make life-changing treatments for patients.

“This successful Series C round demonstrates strong confidence in our vision and capabilities,” said Andrew Adamovich, CEO of AdvanCell. “We are grateful for the continued support from our existing investors, particularly the long-term support from Morningside and are excited to welcome new partners who share our commitment to transforming cancer care. With this funding, AdvanCell is well-positioned to scale our manufacturing operations and progress our cutting-edge therapies towards commercialization.”

The Series C funding represents a significant step in AdvanCell’s journey to become a global leader in radionuclide-based cancer therapeutics.

About AdvanCell

AdvanCell is dedicated to developing innovative cancer therapies that harness the power of targeted alpha-emitting radionuclides. By combining advanced manufacturing capabilities with cutting-edge science and clinical development capabilities, AdvanCell aims to deliver novel treatments that improve outcomes for cancer patients globally. For more information, visit www.advancell.com.au.

About SV Health Investors

SV Health Investors is a leading healthcare fund manager committed to investing in tomorrow’s healthcare breakthroughs. The SV funds invest across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, medical devices, healthcare growth and healthcare technology. With approximately $2bn in assets under management and a truly transatlantic presence with offices in Boston and London, SV has built an extensive network of talented investment professionals and experienced industry veterans. Since its founding in 1993, SV has invested in, created and built more than 200 companies attracting global talent, entrepreneurs and pharma partners. To date, these investments have resulted in the licensing of 26 novel drugs and six new drug classes able to treat indications with unmet medical needs and deliver positive impact to patients. For more information, please visit www.svhealthinvestors.com.

About Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi, focused on investing in promising early-stage healthcare companies. The firm supports pioneering innovations in biotechnology, digital health, and life sciences that align with Sanofi’s mission to bring life-changing treatments to patients worldwide. For more information, please visit www.sanofiventures.com.

About Abingworth

Abingworth is a leading transatlantic life sciences investment firm and part of the global investment firm Carlyle (NASDAQ: CG). Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. Since 1973, Abingworth has invested in over 185 life science companies, leading to 50+ M&As and more than 75 IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston. For more information, please visit www.abingworth.com.

About SymBiosis Capital Management

SymBiosis is an investment firm focused on advancing biotherapeutics innovations for serious and life-threatening diseases. The firm invests in groundbreaking medicines across disease areas, financing stages, and geography, with a focus on programs in, or about to enter, human trials. SymBiosis currently manages a portfolio of more than 30 investments and has significant, long-term capital commitments to fund future investments. For more information, please visit www.symbiosis.vc or follow us on LinkedIn.


Contact details:

For media inquiries, please contact:
Andrew Adamovich
CEO
Email: contact@advancell.com.au
Phone: +612 8000 4199

Media

Images

AdvanCell_0909FF.jpg

Download media

More from this category

  • Medical Health Aged Care, Science
  • 14/03/2025
  • 11:30
AGRF Ltd.

Polygenic Risk Scores: A game-changer for disease prevention and personalised healthcare.

Genomics is revolutionising healthcare, and Polygenic Risk Scores (PRS) are at the forefront of this transformation. By analysing thousands of genetic variants associated with common diseases, PRS provides powerful insights into an individual’s risk of developing conditions such as cardiovascular disease, cancer, and diabetes. This advancement is shaping the way for more effective prevention and personalised management strategies. Integrating PRS with existing genomic services enhances its accessibility and impact. AGRF is now offering PRS powered by the Allelica PREDICT module, a cutting-edge platform that translates genomic data into actionable risk assessments. By combining PRS with genotyping technologies, healthcare providers can…

  • Government NSW, Medical Health Aged Care
  • 14/03/2025
  • 09:25
Health Services Union NSW

Inquiry into Northern Beaches Hospital welcome and overdue

Inquiry into Northern Beaches Hospital welcome and overdue The Health Services Union (HSU) welcomes the announcement of the NSW Parliament's Public Accounts Committee inquiry into the safety and quality of health services at Northern Beaches Hospital, while emphasising that this investigation is long overdue.****DOORSTOP****##Gerard Hayes will hold a doorstop at 11am, at Martin Place, between George and Pitt Street##HSU Secretary Gerard Hayes said the union has been raising serious concerns about the hospital's operations since its opening in 2018,highlighting fundamental flaws in the public-private partnership model."This inquiry must thoroughly examine how a profit-driven healthcare model is affecting patient care, staff…

  • Federal Election, Medical Health Aged Care
  • 14/03/2025
  • 09:05
Australian College of Nursing

SEVEN-POINT PLAN FOR IMMEDIATE EFFECTIVE HEALTH REFORM

JOINT STATEMENT SEVEN-POINT PLAN FOR IMMEDIATE EFFECTIVE HEALTH REFORM A Unified Call from Australia’s Peak Nursing and Midwifery Groups 14 March 2025 Australia’s peak nursing and midwifery groups are calling on the major parties at this election to commit to immediate and effective reform that will provide all Australians with quicker and more affordable access to the health services they need. The nine peak groups are advocating seven nursing-led reforms to improve care, reduce waiting times, and deliver better health outcomes with minimal impact on the budget. The Peaks are calling for commitments to: ACTION 1: Enable Nurse Practitioners and…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.